Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure
© 2020 John Wiley & Sons Ltd..
BACKGROUND: The impact of pregnancy on levels of biologic agents in patients with IBD is undefined and time to elimination in vedolizumab-exposed infants is unknown.
AIMS: To determine the effect of pregnancy on infliximab, adalimumab and vedolizumab levels and to study infant vedolizumab clearance METHODS: In a prospective observational study, maternal drug levels were measured pre-conception, in each trimester, at delivery and postpartum. The association between drug levels and gestation in weeks was assessed using generalised estimating equation modelling. Infant vedolizumab levels were performed at birth (cord blood), 6 weeks and 3 months or until undetectable.
RESULTS: We included 50 IBD patients (23 on infliximab, 15 on adalimumab and 12 on vedolizumab) with at least two intrapartum observations, plus 5 patients on vedolizumab with only mother and baby samples at delivery. Modelling showed no change in adalimumab levels, an increase in infliximab levels of 0.16 (95% CI 0.08-0.24) µg/L/week (P < 0.001) and a decrease of 0.18 (95% CI: -0.33 to -0.02) µg/L/week (P = 0.03) for vedolizumab. In 17 mother-baby pairs, median infant vedolizumab levels at birth were lower than maternal levels (P < 0.05) with an infant:maternal ratio of 0.7 (IQR 0.5-0.9). Vedolizumab was undetectable between 15 and 16 weeks of age in all 12 infants completing follow-up testing.
CONCLUSIONS: During pregnancy, adalimumab levels remain stable, while infliximab levels increase and vedolizumab levels decrease. However, the increments were small suggesting that intrapartum therapeutic drug monitoring and dose adjustment are not indicated. Unlike infliximab and adalimumab, infant vedolizumab levels are lower in cord blood than in mothers and appear to clear rapidly.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:52 |
|---|---|
| Enthalten in: |
Alimentary pharmacology & therapeutics - 52(2020), 10 vom: 30. Nov., Seite 1551-1562 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Flanagan, Emma [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9RV78Q2002 |
|---|
| Anmerkungen: |
Date Completed 19.01.2021 Date Revised 19.01.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/apt.16102 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315518464 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315518464 | ||
| 003 | DE-627 | ||
| 005 | 20231225155106.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/apt.16102 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1051.xml |
| 035 | |a (DE-627)NLM315518464 | ||
| 035 | |a (NLM)32981127 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Flanagan, Emma |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.01.2021 | ||
| 500 | |a Date Revised 19.01.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: The impact of pregnancy on levels of biologic agents in patients with IBD is undefined and time to elimination in vedolizumab-exposed infants is unknown | ||
| 520 | |a AIMS: To determine the effect of pregnancy on infliximab, adalimumab and vedolizumab levels and to study infant vedolizumab clearance METHODS: In a prospective observational study, maternal drug levels were measured pre-conception, in each trimester, at delivery and postpartum. The association between drug levels and gestation in weeks was assessed using generalised estimating equation modelling. Infant vedolizumab levels were performed at birth (cord blood), 6 weeks and 3 months or until undetectable | ||
| 520 | |a RESULTS: We included 50 IBD patients (23 on infliximab, 15 on adalimumab and 12 on vedolizumab) with at least two intrapartum observations, plus 5 patients on vedolizumab with only mother and baby samples at delivery. Modelling showed no change in adalimumab levels, an increase in infliximab levels of 0.16 (95% CI 0.08-0.24) µg/L/week (P < 0.001) and a decrease of 0.18 (95% CI: -0.33 to -0.02) µg/L/week (P = 0.03) for vedolizumab. In 17 mother-baby pairs, median infant vedolizumab levels at birth were lower than maternal levels (P < 0.05) with an infant:maternal ratio of 0.7 (IQR 0.5-0.9). Vedolizumab was undetectable between 15 and 16 weeks of age in all 12 infants completing follow-up testing | ||
| 520 | |a CONCLUSIONS: During pregnancy, adalimumab levels remain stable, while infliximab levels increase and vedolizumab levels decrease. However, the increments were small suggesting that intrapartum therapeutic drug monitoring and dose adjustment are not indicated. Unlike infliximab and adalimumab, infant vedolizumab levels are lower in cord blood than in mothers and appear to clear rapidly | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a vedolizumab |2 NLM | |
| 650 | 7 | |a 9RV78Q2002 |2 NLM | |
| 650 | 7 | |a Infliximab |2 NLM | |
| 650 | 7 | |a B72HH48FLU |2 NLM | |
| 650 | 7 | |a Adalimumab |2 NLM | |
| 650 | 7 | |a FYS6T7F842 |2 NLM | |
| 700 | 1 | |a Gibson, Peter R |e verfasserin |4 aut | |
| 700 | 1 | |a Wright, Emily K |e verfasserin |4 aut | |
| 700 | 1 | |a Moore, Gregory T |e verfasserin |4 aut | |
| 700 | 1 | |a Sparrow, Miles P |e verfasserin |4 aut | |
| 700 | 1 | |a Connell, William |e verfasserin |4 aut | |
| 700 | 1 | |a Kamm, Michael A |e verfasserin |4 aut | |
| 700 | 1 | |a Begun, Jakob |e verfasserin |4 aut | |
| 700 | 1 | |a Christensen, Britt |e verfasserin |4 aut | |
| 700 | 1 | |a De Cruz, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Shelton, Edward |e verfasserin |4 aut | |
| 700 | 1 | |a Dowling, Damian |e verfasserin |4 aut | |
| 700 | 1 | |a Andrews, Jane M |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Steven J |e verfasserin |4 aut | |
| 700 | 1 | |a Niewiadomski, Olga |e verfasserin |4 aut | |
| 700 | 1 | |a Ward, Mark G |e verfasserin |4 aut | |
| 700 | 1 | |a Rosella, Ourania |e verfasserin |4 aut | |
| 700 | 1 | |a Rosella, Gennaro |e verfasserin |4 aut | |
| 700 | 1 | |a Kiburg, Katerina V |e verfasserin |4 aut | |
| 700 | 1 | |a Ross, Alyson L |e verfasserin |4 aut | |
| 700 | 1 | |a Bell, Sally J |e verfasserin |4 aut | |
| 700 | 0 | |a PICCOLO Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Alimentary pharmacology & therapeutics |d 1992 |g 52(2020), 10 vom: 30. Nov., Seite 1551-1562 |w (DE-627)NLM012692506 |x 1365-2036 |7 nnns |
| 773 | 1 | 8 | |g volume:52 |g year:2020 |g number:10 |g day:30 |g month:11 |g pages:1551-1562 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/apt.16102 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 52 |j 2020 |e 10 |b 30 |c 11 |h 1551-1562 | ||